Cargando…

Histone Modifications and Their Targeting in Lymphoid Malignancies

In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández-Serrano, Miranda, Winkler, René, Santos, Juliana C., Le Pannérer, Marguerite-Marie, Buschbeck, Marcus, Roué, Gaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745418/ https://www.ncbi.nlm.nih.gov/pubmed/35008680 http://dx.doi.org/10.3390/ijms23010253

Ejemplares similares

Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy
por: Maher, Michael, et al.
Publicado: (2021)

Histone Variants and Their Chaperones in Hematological Malignancies
por: Kirkiz, Ecem, et al.
Publicado: (2023)

Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer
por: Corujo, David, et al.
Publicado: (2018)

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients
por: Le Pannérer, Marguerite-Marie, et al.
Publicado: (2022)

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
por: Ribeiro, Marcelo L., et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications
por: Vegliante, Maria Carmela, et al.
Publicado: (2011)

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome
por: Bereshchenko, Oxana, et al.
Publicado: (2019)

RHOA Therapeutic Targeting in Hematological Cancers
por: Santos, Juliana Carvalho, et al.
Publicado: (2023)

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
por: Reyes-Garau, Diana, et al.
Publicado: (2019)

Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18
por: Maher, Michael, et al.
Publicado: (2021)

DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells
por: Nordström, Lena, et al.
Publicado: (2015)

Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis
por: Diesch, Jeannine, et al.
Publicado: (2021)

Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
por: Feng, Jianwei, et al.
Publicado: (2022)

Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells
por: Murata, Makoto, et al.
Publicado: (2000)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Histone Modifications as an Intersection Between Diet and Longevity
por: Molina-Serrano, Diego, et al.
Publicado: (2019)

Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
por: Santos, Juliana Carvalho, et al.
Publicado: (2022)

Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies
por: Clarisse, Dorien, et al.
Publicado: (2017)

Analysis of Myc-Induced Histone Modifications on Target Chromatin
por: Martinato, Francesca, et al.
Publicado: (2008)

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
por: Bajbouj, Khuloud, et al.
Publicado: (2021)

Lymphoid malignancies ARNT unstoppable
por: Gardella, Kacie A., et al.
Publicado: (2016)

The Role of MacroH2A Histone Variants in Cancer
por: Hsu, Chen-Jen, et al.
Publicado: (2021)

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Epigenetic targets in B- and T-cell lymphomas: latest developments
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies
por: Frazzi, Raffaele, et al.
Publicado: (2016)

Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy
por: Zhao, Xia, et al.
Publicado: (2013)

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022)

Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency.
por: Ramsden, C. S., et al.
Publicado: (1991)

ANTIGEN-INDUCED CHANGES IN LYMPHOID CELL HISTONES : I. Thymus
por: Black, Maurice M., et al.
Publicado: (1965)

The EHA Research Roadmap: Malignant Lymphoid Diseases
por: Dreyling, Martin, et al.
Publicado: (2022)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Epigenetic mechanisms of Immune remodeling in sepsis: targeting histone modification
por: Wu, Dan, et al.
Publicado: (2023)

Development of venetoclax for therapy of lymphoid malignancies
por: Zhu, Huayuan, et al.
Publicado: (2017)

Effects of COVID-19 in lymphoid malignancies
por: Özdemir, Öner
Publicado: (2021)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells
por: Collins, Hilary M, et al.
Publicado: (2013)

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
por: Zain, Jasmine, et al.
Publicado: (2010)

NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy
por: Grondona, Paula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0un4kncubtv35v6qrckjkoh7il